NP PHARMA
ActiveNP PHARMA has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €41k and a net result of €38k. Its solvency ranks better than 76% of 18039 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.2% (low).
Checked score
Score 2025
82
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes
Profitability100
Solvency90
Growth-
Track record67
Bankruptcy probability, 12 months
1.2%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €3k at 30 days acceptable
Liquidity ample (current ratio 2.81; short-term debt: 35% and cash: 86.7% of total assets), and 35% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
65%
Return on assets
60.2%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 04-07-2026, 27 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
27 d early
← before the deadline
after the deadline →
Financials · fiscal year 2025, micro schema
Equity
€41k
Total assets
€63k
Net result
€38k
Working capital
€40k
Turnover and EBIT margin not published: the micro schema does not require them.
Balance-sheet composition
Assets €63k
Fixed assets
€979
Current assets
€62k
Equity and liabilities €63k
Equity
€41k
Debt
€22k
Debt finances 35.0% of the balance-sheet total.
Key figures and ratios
EBITDA
€51k
Cash flow
€38k
Solvency
65.0%
Current ratio
2.81
Quick ratio
2.81
Debt / equity
0.54
ROE
92.6%
ROA
60.2%
Interest coverage
1204.73
Debt
€22k
Debt ≤ 1 year
€22k
Income taxes
€13k
Filed annual accounts
As filed with the NBB · 2025
Balance sheet
Code2025
Assets
Total assets20/58€63k
Fixed assets21/28€979
Tangible fixed assets22/27€979
Plant, machinery and equipment23€979
Current assets29/58€62k
Amounts receivable within one year40/41€7k
Trade receivables40€7k
Cash at bank and in hand54/58€54k
Deferred charges and accrued income490/1€223
Equity and liabilities
Total equity and liabilities10/49€63k
Equity10/15€41k
Contributions10/11€3k
Profit (loss) carried forward14€38k
Amounts payable17/49€22k
Amounts payable within one year42/48€22k
Trade debts44€757
Suppliers440/4€757
Taxes, remuneration and social security45€20k
Taxes450/3€18k
Remuneration and social security454/9€2k
Other amounts payable47/48€1k
Income statement
Code2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€99
Other operating charges640/8€541
Gross operating margin9900€51k
Operating profit (loss)9901€51k
Financial charges65/66B€42
Recurring financial charges65€42
Profit (loss) for the period before taxes9903€51k
Income taxes67/77€13k
Profit (loss) for the period9904€38k
Profit (loss) for the period to be appropriated9905€38k
Appropriation of the result
Profit (loss) to be appropriated9906€38k
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2026
04-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
NBB filing
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Mons · 1 establishment unit since 2025
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Résidence du Rieu 87030 MonsGround area
1,245 m²
Building footprint
122 m²
Volume, LiDAR
613 m³
Parcel 53071B0412/00A002, Wallonia · tallest building 6.8 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
NP PHARMA
since 20252.370.190.941
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 53071B0412/00A002 | Wallonia | 1,245 m² | 1 · 122 m² | 6.8 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMACIE SCHOONEJANS
BE 0842.619.994
Sint-Gillis (bij-Brussel) · Eq €41k
SANASPE
BE 0874.832.607
Anderlecht · Eq €41k
APOTHEEK A. JANSSENS
BE 0875.061.942
Maasmechelen · Eq €41k
PHARMACIE CONSCIENCE
BE 0560.775.212
Evere · Eq €40k
De Laere Pharma
BE 0763.546.683
Koksijde · Eq €40k
Of 5,224 companies in sector 47730 we hold annual accounts for 3,864. 2,459 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded13-02-2025
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
79901Tourist information services
Sources
Crossroads Bank for EnterprisesNational Bank · 1 filingAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.